I'd just add that ongoing surveillance of this nature is really very key to our life cycle management. I mean, this is why we're asking for these tools, to be able to coordinate.
On January 31st, 2008. See this statement in context.
On January 31st, 2008. See this statement in context.
January 31st, 2008 / 12:55 p.m.
Director, Office of Patented Medicines and Liaison, Therapeutic Products Directorate, Department of Health
I'd just add that ongoing surveillance of this nature is really very key to our life cycle management. I mean, this is why we're asking for these tools, to be able to coordinate.
See context to find out what was said next.